新型皮内注射装置Immucise™的性能与可用性评估及老年人流感疫苗皮内接种试验再分析
本文总结Immucise™皮内注射系统的设计,并报告其性能与可用性测试结果,显示该装置可减少死体积并将药物精准注入从婴儿到老年人的皮内组织,医护人员可正确安全使用。一项随机对照试验比较Immucise™皮内接种与标准皮下接种季节性流感疫苗在老年人群中的效果,发现接种后90天和180天皮内组疫苗效果与皮下组相当或更优,且两剂皮内组几何平均滴度值(尤其B株)高于两剂皮下组。
要点
- Immucise™可减少死体积并将药物精准注入从婴儿到老年人的皮内组织。
- 医护人员可正确安全地使用Immucise™。
- 老年人接种后180天内皮内组流感疫苗效果与皮下组相当或更优。
核心结论
- Immucise™是将少量疫苗快速广泛分配至更多人群且疫苗损失少的较优装置之一。
研究设计与样本
- 总结Immucise™皮内注射系统的设计并报告其性能与可用性测试结果。
- 随机对照试验比较Immucise™皮内接种与标准皮下接种季节性流感疫苗在老年组中的效果,分析接种后90天和180天的疫苗效力。
主要发现
- Immucise™可减少死体积并将药物精准注入从婴儿到老年人的皮内组织。
- 医护人员可正确安全地使用Immucise™。
- 接种后90天和180天,皮内组疫苗效果与皮下组相当或更优。
- 两剂皮内组几何平均滴度值(尤其B株)高于两剂皮下组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Under the pandemic situation, there is an urgent need to produce and acquire sufficient quantities of prophylactic vaccines. It becomes important to devise a way to achieve reliable immunity with lower doses to distribute limited supplies of vaccines to maximum number of people very quickly. Intradermal (ID) vaccination is one such method to increase the effectiveness of vaccines. However, this method has not been widely used in general clinical practice because it is technically difficult to inject vaccines precisely into the ID tissue. Therefore, new ID delivery systems that allow reliable ID administration are under development. In this paper, we summarize its design and present the results of performance and usability testing for the Immucise™ Intradermal Injection System (Immucise™). This study showed that Immucise™ can reduce dead volume and inject drugs precisely into the ID tissues of subjects from infants to the elderly and can be used correctly and safely by healthcare professionals. This randomized controlled trial compared ID administration with Immucise™ and standard subcutaneous (SC) administration of seasonal influenza vaccine by analyzing the efficacy of the vaccine in the elderly group at 90 days and 180 days after administration. It was found that the vaccine for the ID group was as effective or more effective than that for the SC group up to 180 days later. It was also found that the geometric mean titer values, especially for B strains, were higher in the two-dose ID group than in the two-dose SC group. These findings suggest that Immucise™ is one of the best devices to distribute a small amount of vaccine quickly and widely to a larger number of people with little loss of vaccine during a pandemic.
引用
- Shimizu S, Tanaka R, Itoh E, et al. Performance and usability evaluation of novel intradermal injection device Immucise™ and reanalysis of intradermal administration trials of influenza vaccine for the elderly. Vaccine. 2022. PMID: 35031147. doi:10.1016/j.vaccine.2021.12.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。